Regeneron Pharmaceuticals, Inc. (REGN) Competitors & Peers
The 5 companies closest to Regeneron Pharmaceuticals, Inc. on the factors that matter — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| VRTX | Peer | $523.91 | P/E 28.9RSI 70Cap 132.7 B |
| ARGX | Peer | $866.11 | P/E 33.0RSI 49Cap 54.2 B |
| RVMD | Peer | $206.97 | RSI 68Cap 44.4 B |
| CSLLY | Peer | $23.77 | P/E 15.2RSI 68Cap 45.5 B |
| CMXHF | Peer | $93.67 | P/E 14.9RSI 70Cap 44.9 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- SAN.PAPartner
Sanofi and Regeneron have a landmark antibody collaboration — Sanofi commercializes Dupixent globally and both share profits. Dupixent generated $17.8B in global net sales in 2025.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- SNYPartner
Sanofi + Regeneron Dupixent + Libtayo immunology collaboration.
Model-inferred, unverified — treat as a lead, not evidence - KNSASupplier
Regeneron developed and licensed Arcalyst to Kiniksa, receiving royalties on sales.
Model-inferred, unverified — treat as a lead, not evidence - AMGNCompetitor
Amgen is a direct competitor, notably clashing over PCSK9 inhibitor patents (Repatha vs Praluent).
Model-inferred, unverified — treat as a lead, not evidence - NTLAPartner
Regeneron is collaborating with and investing in Intellia to develop in vivo CRISPR/Cas9-based therapies.
Model-inferred, unverified — treat as a lead, not evidence - SNYPartner
Regeneron and Sanofi have a massive global collaboration for the development and commercialization of Dupixent and other antibodies.
Model-inferred, unverified — treat as a lead, not evidence - BAYN.DEPartner
Regeneron and Bayer collaborate globally on the blockbuster ophthalmology drug Eylea.
Model-inferred, unverified — treat as a lead, not evidence - ROG.SWPartner
Regeneron partnered with Roche to manufacture, develop, and distribute Ronapreve globally.
Model-inferred, unverified — treat as a lead, not evidence - ALNYPartner
Regeneron and Alnylam are partnered on discovering and developing RNAi therapeutics for eye and central nervous system diseases.
Model-inferred, unverified — treat as a lead, not evidence - NVSCompetitor
Novartis competes directly in the ophthalmology space (e.g., Lucentis and Beovu) against Eylea.
Model-inferred, unverified — treat as a lead, not evidence - CTMXPartner
Regeneron partnered with CytomX to create conditionally activated bispecific immunotherapies.
Model-inferred, unverified — treat as a lead, not evidence - OCSCompetitor
Competes in DME treatments; OCS-01 aims to replace Regeneron's Eylea (eye injection) with a topical eye drop.
Model-inferred, unverified — treat as a lead, not evidence - ABBVCompetitor
Regeneron and AbbVie compete in immunology/dermatology — Dupixent (dupilumab, IL-4/13) vs Rinvoq (upadacitinib, JAK) and Skyrizi (risankizumab, IL-23) for atopic dermatitis.
Model-inferred, unverified — treat as a lead, not evidence - NTLAPartner
Intellia + Regeneron collaboration on in-vivo TTR amyloidosis.
Model-inferred, unverified — treat as a lead, not evidence - REPLPartner
Collaborates on clinical trials combining RP1 with Regeneron's PD-1 inhibitor Libtayo (cemiplimab).
Model-inferred, unverified — treat as a lead, not evidence - KODCompetitor
Kodiak's tarcocimab targets eye diseases served by Regeneron's Eylea.
Model-inferred, unverified — treat as a lead, not evidence - SWTXPartner
Regeneron and SpringWorks collaborate on combinations targeting multiple oncology pathways.
Model-inferred, unverified — treat as a lead, not evidence - LLYCompetitor
Regeneron and Lilly compete in immunology/dermatology — Dupixent vs Lilly's Lebrikizumab (IL-13) for atopic dermatitis.
Model-inferred, unverified — treat as a lead, not evidence - MCKSupplier
McKesson is one of Regeneron's primary pharmaceutical wholesale distributors in the US, distributing Eylea, Dupixent, and other products.
Model-inferred, unverified — treat as a lead, not evidence